Vicente Peg1, Irene Sansano2, Begoña Vieites3, Laia Bernet4, Rafael Cano5, Alicia Córdoba6, Magdalena Sancho7, María Dolores Martín8, Felip Vilardell9, Alicia Cazorla10, Martín Espinosa-Bravo11, José Manuel Pérez-García12, Javier Cortés13, Isabel T Rubio11, Santiago Ramón Y Cajal2. 1. Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Morphological Sciences Department, Universidad Autónoma de Barcelona, Spain. Electronic address: vpeg@vhebron.net. 2. Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Morphological Sciences Department, Universidad Autónoma de Barcelona, Spain. 3. Pathology Department, Virgen del Rocío University Hospital, Sevilla, Spain. 4. Pathology Department, Hospital Lluis Alcanys, Xàtiva, Spain. 5. Pathology Department, Hospital de la Ribera, Alcira, Spain. 6. Pathology Department, Hospital de Navarra, Pamplona, Spain. 7. Pathology Department, Salamanca University Hospital, Spain. 8. Pathology Department, Complejo Hospitalario de Jaén, Spain. 9. Pathology Department, Hospital Arnau de Vilanova, Lérida, Spain. 10. Pathology Department, Fundación Jiménez Díaz, Madrid, Spain. 11. Breast Cancer Unit, Vall d'Hebron University Hospital, Barcelona, Spain. 12. Medical Oncology Department, Baselga Institute of Oncology, Quiron Hospital, Barcelona, Spain. 13. Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Oncology Institute, Barcelona, Spain.
Abstract
BACKGROUND: Axillary staging (pN) is considered one of the most important prognostic factors in breast cancer patients. However, the Z0011 study data drastically reduced the number of surgical axillary dissections in a selected group of patients, limiting the prognostic information relating to axillary involvement to the sentinel lymph node (SLN). It is known that there is a relationship between SLN total tumour load (TTL) and axillary involvement. The objective of this study is to analyse the relationship between the TTL and outcomes in patients with early stage breast cancer. PATIENTS AND METHODS: clinicopathological and follow-up data were collected from 950 patients with breast cancer between 2009 and 2010 on whom SLN analysis was conducted by molecular methods (One Step Nucleic Acid Amplification, Sysmex, Kobe, Japan). RESULTS: TTL (defined as the total number of CK19 mRNA copies in all positive SLN) correlates with disease free survival (HR, 1.08; p = 0.000004), with local recurrence disease free survival (HR = 1.07; p = 0.0014) and overall survival (HR: 1.08, p = 0.0032), clearly defining a low-risk group (TTL <2.5 × 104 CK19 mRNA copies/μL) versus a high-risk group (>2.5 × 104 CK 19 mRNA copies/μL). CONCLUSIONS: SLN TTL permits the differentiation between two patient groups in terms of DFS and OS, independently of axillary staging (pN), age and tumour characteristics (size, grade, lymphovascular invasion). This new data confirms the clinical value of low axillary involvement and could partially replace the information that staging of the entire axilla provides in patients on whom no axillary lymph node dissection is performed.
BACKGROUND: Axillary staging (pN) is considered one of the most important prognostic factors in breast cancerpatients. However, the Z0011 study data drastically reduced the number of surgical axillary dissections in a selected group of patients, limiting the prognostic information relating to axillary involvement to the sentinel lymph node (SLN). It is known that there is a relationship between SLN total tumour load (TTL) and axillary involvement. The objective of this study is to analyse the relationship between the TTL and outcomes in patients with early stage breast cancer. PATIENTS AND METHODS: clinicopathological and follow-up data were collected from 950 patients with breast cancer between 2009 and 2010 on whom SLN analysis was conducted by molecular methods (One Step Nucleic Acid Amplification, Sysmex, Kobe, Japan). RESULTS: TTL (defined as the total number of CK19 mRNA copies in all positive SLN) correlates with disease free survival (HR, 1.08; p = 0.000004), with local recurrence disease free survival (HR = 1.07; p = 0.0014) and overall survival (HR: 1.08, p = 0.0032), clearly defining a low-risk group (TTL <2.5 × 104 CK19 mRNA copies/μL) versus a high-risk group (>2.5 × 104 CK 19 mRNA copies/μL). CONCLUSIONS: SLN TTL permits the differentiation between two patient groups in terms of DFS and OS, independently of axillary staging (pN), age and tumour characteristics (size, grade, lymphovascular invasion). This new data confirms the clinical value of low axillary involvement and could partially replace the information that staging of the entire axilla provides in patients on whom no axillary lymph node dissection is performed.
Authors: B Vieites; M Á López-García; M D Martín-Salvago; C L Ramirez-Tortosa; R Rezola; M Sancho; L López-Vilaró; F Villardell; O Burgués; B Fernández-Rodriguez; L Alfaro; V Peg Journal: Clin Transl Oncol Date: 2021-01-31 Impact factor: 3.405
Authors: Sherley Diaz-Mercedes; Ivan Archilla; Jordi Camps; Antonio de Lacy; Iñigo Gorostiaga; Dulce Momblan; Ainitze Ibarzabal; Joan Maurel; Nuria Chic; Josep Antoni Bombí; Francesc Balaguer; Antoni Castells; Iban Aldecoa; Josep Maria Borras; Miriam Cuatrecasas Journal: Appl Health Econ Health Policy Date: 2019-10 Impact factor: 2.561
Authors: Bello Inua; Victoria Fung; Nour Al-Shurbasi; Sarah Howells; Olga Hatsiopoulou; Praveen Somarajan; Gregory J Zardin; Norman R Williams; Stan Kohlhardt Journal: Mol Clin Oncol Date: 2021-01-21
Authors: Enrique Trilla; Juan Morote; Mercè Cuadras; Jacques Planas; Ana Celma; Lucas Regis; Inés M de Torres; M Eugenia Semidey Journal: BMC Cancer Date: 2022-04-02 Impact factor: 4.430
Authors: Manuel Algara López; Elvira Rodríguez García; Inmaculada Beato Tortajada; Francisco José Martínez Arcelus; Juan Salinas Ramos; José Reyes Rodríguez Garrido; Xavier Sanz Latiesas; Ana Soler Rodríguez; Germán Juan Rijo; Amanda Flaquer García Journal: Radiat Oncol Date: 2020-10-02 Impact factor: 3.481